摘要 Objective: Prostate cancer in elderly patients was formerly treated with androgen deprivation therapy. Since the latter of the 1990s new technologies were introduced into treatments, then strategies have varied. We aimed to observe the outcomes of elderly patients treated during transition period and compare each stage with others. Methods: During 2008 and 2010, 255 patients with prostate cancer older than 75 years were sequentially treated. With exception of patients with bone and/or visceral metastasis, outcomes of 199 patients with localized and locally advanced stages were examined. Complete records were obtained by the end of 2015. Results: In total, 122 (61%), 28 (14%), 37 (19%) and 12 (6%) of patients were in stages T1c-T2a, T2b-c, T3 and T4, respectively. Patients generally presented with abnormal screening or lower urinary tract symptom. Seventy-one percent of patients received androgen deprivation therapy as monotherapy and 22% of the radiation-treated patients added androgen deprivation therapy. Patients in stage T1c-T2a and T2b-c showed a favorable prognosis. Some cancer death appeared in patients with T3 and T4 during observation periods. Twenty-seven percent of patients died from prostate cancer-independent complications:pneumonia, heart disease, and brain vascular disease. Tendency is similar to that of Japanese elderly male population. No remarkable side effects from androgen deprivation therapy were noticed. Conclusion: Elderly patients with localized prostate cancer showed favorable prognosis by androgen deprivation therapy with/without radiation, thus efficacy of androgen deprivation therapy is suitable to elderly patients with applicable stages. Prognosis of patients with locally advanced stage is serious and remains to be improved.
Abstract: Objective: Prostate cancer in elderly patients was formerly treated with androgen deprivation therapy. Since the latter of the 1990s new technologies were introduced into treatments, then strategies have varied. We aimed to observe the outcomes of elderly patients treated during transition period and compare each stage with others. Methods: During 2008 and 2010, 255 patients with prostate cancer older than 75 years were sequentially treated. With exception of patients with bone and/or visceral metastasis, outcomes of 199 patients with localized and locally advanced stages were examined. Complete records were obtained by the end of 2015. Results: In total, 122 (61%), 28 (14%), 37 (19%) and 12 (6%) of patients were in stages T1c-T2a, T2b-c, T3 and T4, respectively. Patients generally presented with abnormal screening or lower urinary tract symptom. Seventy-one percent of patients received androgen deprivation therapy as monotherapy and 22% of the radiation-treated patients added androgen deprivation therapy. Patients in stage T1c-T2a and T2b-c showed a favorable prognosis. Some cancer death appeared in patients with T3 and T4 during observation periods. Twenty-seven percent of patients died from prostate cancer-independent complications:pneumonia, heart disease, and brain vascular disease. Tendency is similar to that of Japanese elderly male population. No remarkable side effects from androgen deprivation therapy were noticed. Conclusion: Elderly patients with localized prostate cancer showed favorable prognosis by androgen deprivation therapy with/without radiation, thus efficacy of androgen deprivation therapy is suitable to elderly patients with applicable stages. Prognosis of patients with locally advanced stage is serious and remains to be improved.
[1] National Institute of Cancer Research of Japan. http://gamnjoho.jp. [2] Busch J, Magheli A, Leva N, Ferrari M, Kraer J, klopf C, et al. Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. BJU Int 2014;114:517-21. [3] Roussael B, Ouelletr GM, Mohile SG, Dale W. Prostate cancer in elderly men: screening, active surveillance, and definitive therapy. Clin Geriatr Med 2015;31:615-29. [4] Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010;106:462-9. [5] Berger I, Boehmer F, Ponholzer A, Madersbacher S. Prostate cancer in senior adults: over-or undertreated? Wien Med Wochenschr 2009;159:521-8. [6] Fung C, Dale W, Mohile SG. Prostate cancer in the elderly patient. J Clin Oncol 2014;20:2523-30. [7] Tay KJ, Moul JW, Armstrong AJ. Management of prostate cancer in the elderly. Clin Geriatr Med 2016;32:113-32. [8] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. [9] Epstein JI, Allsbrook WC, Amin MB, Egevad LL, ISUP Grading Commitee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-42. [10] National Comprehensive Cancer Network Guidelines. Prostate Cancer ver 2.2016. NCCN org. Port Washington PA USA. http://www.nccn.org/ [11] Sammon JD, Abdollah F, D'Amico A, Gettman M, Haese A, Suardi N, et al. Predicting life expectancy in men diagnosed with prostate cancer. Eur Urol 2015;68:756-65. [12] Fitzpatrick JM. Management of localized prostate cancer in senior adults: the crucial role of comorbidity. BJU Int 2008; 101:16-22. [13] Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol 2015;68: 53-68. [14] Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol 2015;68:480-6. [15] Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for old men with locally advanced prostate cancer. J Clin Oncol 2015;33:716-22. [16] Daskivich TJ, Lai J, Dick AV, Setodji CM, Hanley JM, Litwin MS, et al. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis. Cancer 2014;120:2432-9. [17] Mitsuzuka K, Arai Y. Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy. Int J Clin Oncol 2014;19: 793-879. [18] Daskivich TJ, Lai J, Dick AW, Setodji CM, Hanley JM, Litwin MS, et al. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer 2014;120:3642-50. [19] Life table. Ministry of Health, Labor and Welfare of Japan; 2015. www.mhlw.go.jp/toukei/saikin/hw/life/life14/index.html. [20] Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 2013; 158:709-17. [21] Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, et al. Improved prediction of long-term, other cause mortality in men with prostate cancer. J Urol 2011;186:1868-73. [22] Daskivich TJ, Kwan L, Dash A, Greenfield S, Litwin MS. Weighted versus unweighted Charlson score to predict longterm other-cause mortality in men with early-stage prostate cancer. Eur Urol 2014;66:1002-9. [23] Jespersen CG, Norgaard M, Jacobsen JB, Borre M. Patient comorbidity is associated with conservative treatment of localized prostate cancer. Scand J Urol 2015;22:1-5. [24] Kenzik KM, Morey MC, Cohen HJ, Sloane R, Demark-Wahnefried W. Symptoms, weight loss, and physical function in a lifestyle intervention study of older cancer survivors. J Geriatr Oncol 2015;6:424-32. [25] Lu-Yao GL, Albertsen PC, Moor DF, Lin Y, DiPaola RS, Yao SL. Fifteen year outcomes following conservative management among men aged 65 years or older with localized prostate cancer. Eur Urol 2015;68:805-11. [26] D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-5. [27] Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009;181: 1998-2008. [28] Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Hemelrijck MV. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer; A meta-analysis. Eur Urol 2015;68:386-96. [29] Abdollah F, Sammon JD, Reznor G, Sood A, Schmid M, Klett DE, et al. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged 66 years. Eur J Surg Oncol 2015;41:1529-39. [30] Nguyen PL, Alibhal SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67: 825-36. [31] Wang LH, Liu CK, Chen CH, Kao LT, Lin HC, Huang CY. No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. Andrology 2015;4:128-32. [32] Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. Current status of endocrine therapy for prostate cancer in Japan e analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 2007; 37:775-81. [33] Kitagawa Y, Hinotsu S, Shigehara K, Nakashima K, Kawaguchi S, Yaegashi H, et al. Japan cancer of the prostate risk assessment for combined androgen blockade including bicalutamide: clinical application and validation. Int J Urol 2013;20:708-14. [34] Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol 2015;17:1-10. [35] Donovan KA, Walker LM, Wassersug RJ, Thompson LMA, Robinson JW. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer 2015;121:4286-99. [36] Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S, Shimazaki J. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen doubling time and nadir prostate-specific antigen. Jpn J Clin Oncol 2008;38:36-42.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
